Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 257

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 257
---
 the Company issues from time to time
hereunder, the “Rights”).

The Company accounts for the rights issued in
connection with the Initial Public Offering in accordance with the guidance contained in ASC 815-40. Such guidance
provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured
at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified
in equity.

F-13

OSR HOLDINGS, INC.

(f/k/a Bellevue Life Sciences Acquisition Corp.) 

NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024

Equity Participation Shares 

At the closing of the
Initial Public Offering, the Company agreed to issue to Chardan 34,500 representative shares (“Equity Participation
Shares”), which include an additional 4,500 shares due to the exercise of the over-allotment option in full, which will
be issued upon the completion of the Initial Business Combination.

The Company complies with the requirements
of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, “Expenses of
Offering.” Offering costs consist principally of professional and registration fees incurred through the date of these
consolidated financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts
that are classified as assets and liabilities are expensed immediately.

Net Income (Loss) per Common Share 

The Company complies with the accounting and disclosure
requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per common share is computed by dividing net income
(loss) by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture.
The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an
aggregate of 7,330,000 shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise
is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss)
per share of common